Granules India Limited has informed the Exchange about Investor Presentation
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Granules India shared its Q1FY26 earnings presentation alongside the results filed earlier the same day. Revenue grew 3% year-on-year to ₹12,101 crore, helped by a 7% rise in North America sales and the first full quarter of contribution from acquired Senn Chemicals AG (₹291 crore). Gross margin expanded sharply to 64.9% from 58.9% a year ago, but EBITDA margin slipped to 20.4% (down 159 basis points YoY) due to a 24% jump in manpower costs from the Senn consolidation. Net profit fell 16% YoY to ₹1,126 crore, dragged by exceptional expenses tied to ongoing litigation settlements (versus a one-time cyber insurance gain in Q4FY25). The company filed 1 ANDA and 2 USDMFs in the quarter, has 91 cumulative USFDA approvals, and spent ₹678 crore on R&D (5.6% of sales). Net debt rose to ₹9,480 crore, lifting net debt/EBITDA to 0.96x from 0.75x the prior quarter.
Mixed quarter for shareholders — top-line and gross margin trends are positive, but higher costs from the Senn integration and litigation-related one-offs pulled down operating profit and net earnings. The rising debt and softer margins may weigh on near-term sentiment, though the strong product pipeline and regulatory momentum provide longer-term support.